Esperion Therapeutis.Inc. buy Bankster
Summary
This prediction ended on 29.03.24 with a price of €2.78. The BUY prediction by Bankster finished with a performance of 3.27%. Bankster has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | 11.827% | 11.827% |
iShares Core DAX® | 1.851% | 5.158% |
iShares Nasdaq 100 | 1.573% | 2.589% |
iShares Nikkei 225® | -0.412% | -2.857% |
iShares S&P 500 | 1.128% | 2.485% |
Comments by Bankster for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Bankster for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
13.03.23
13.03.24
03.04.23